Hepion Pharmaceuticals (NASDAQ:HEPA) shares are trading higher after the company reported its CRV431 demonstrated efficacy in Kidney Fibrosis.

CRV431 is the company’s leading drug candidate. Showing efficacy is positive news and increases investor sentiment around the specific drug.

Hepion Pharmaceuticals is a United States-based biopharmaceutical company engaged in the development of targeted pharmaceutical therapies for liver disease.

Hepion Pharmaceuticals was trading 15.2% higher at $2.88 at time of publication on Tuesday. The stock has a 52-week high of $8.35 and a 52-week low of $1.00.